Expanding CAR-T therapy to other cancers

The FDA has approved CAR-T therapy products for adults with diffuse large B-cell lymphoma and pediatric and young adults suffering from acute lymphoblastic leukemia. Now researchers at Moffitt Cancer Center are working to expand Chimeric Antigen Receptor T-cell (CAR-T) therapy to other cancers. In a new phase 1 trial called the THINK (Therapeutic Immunotherapy with NKG2D) study is investing Celyad’s new CAR-T therapy which genetically modifies immune cell to express a natural killer receptor that targets leukemia tumors. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.